SuperworthActuate Therapeutics EPS ACTU
Diluted earnings per share by quarter and over the last twelve months, from 2023.
- Last 12 months, to Jun 30, 2026
- −$0.88
- Latest quarter, Q2 FY26
- −$0.20
- Fiscal year 2025
- −$1.06
Actuate Therapeutics' earnings per share was −$0.88 over the twelve months to Jun 30, 2026.
In its latest quarter, Q2 FY26, it was −$0.20.
Earnings per share over time
Fiscal year by fiscal year
| Fiscal year | EPS | Change |
|---|---|---|
| FY2025 | −$1.06 | n/a |
| FY2024 | −$10.48 | n/a |
| FY2023 | −$17.19 | n/a |
Each fiscal year is the twelve months to its fourth quarter.
Quarter by quarter
| Quarter | Ended | EPS | On a year earlier | Last 12 months |
|---|---|---|---|---|
| Q2 FY26 | −$0.20 | n/a | −$0.88 | |
| Q1 FY26 | −$0.24 | n/a | −$0.98 | |
| Q4 FY25 | −$0.19 | n/a | −$1.06 | |
| Q3 FY25 | −$0.25 | n/a | −$1.20 | |
| Q2 FY25 | −$0.30 | n/a | −$1.50 | |
| Q1 FY25 | −$0.32 | n/a | −$5.40 | |
| Q4 FY24 | −$0.33 | n/a | −$10.48 | |
| Q3 FY24 | −$0.55 | n/a | −$15.22 | |
| Q2 FY24 | −$4.20 | n/a | −$18.98 | |
| Q1 FY24 | −$5.40 | n/a | −$18.66 | |
| Q4 FY23 | −$5.07 | n/a | −$17.19 | |
| Q3 FY23 | −$4.31 | n/a | n/a |
Against its peers
Companies in Drug Manufacturers - General nearest Actuate Therapeutics' size, closest first, today.
| Company | EPS, 12 months | Growth |
|---|---|---|
| ACTUActuate Therapeutics | −$0.88 | |
| ATNMActinium Pharmaceuticals | $0.36 | |
| SPROSpero Therapeutics | $0.11 | |
| LFVNLifevantage | $0.40 | −46% a year |
| Peer median | $0.36 |
What the EPS figure tells you
Net income divided by diluted shares. The denominator of PE.
One-off charges and gains swing it. The TTM view smooths a single odd quarter.
More on Actuate Therapeutics
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.